<DOC>
	<DOCNO>NCT01656395</DOCNO>
	<brief_summary>The purpose adaptive-design study evaluate dose-related effectiveness safety MK-1029 , alone combination montelukast , compare placebo montelukast alone , treatment persistent asthma adult .</brief_summary>
	<brief_title>A Dose-Ranging Study MK-1029 Adults With Persistent Asthma ( MK-1029-012 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>pregnant breastfeeding , plan become pregnant study history symptom persistent asthma least one year current use acceptable asthma treatment willingness taper discontinue treatment ; acceptable asthma treatment : use inhale SABAs ( e.g. , albuterol/salbutamol ) `` asneeded '' use asthma controller medication ; OR use stable dos low mediumdose inhaled corticosteroid ( ICS ) , alone , combination either longacting betaagonist ( LABA ) asthma controller medication ( include leukotriene receptor antagonist ) tolerate taper discontinuation history smoking OR smoking within &lt; 1 year smoke history ≤10 packyears ability maintain constant day/night , awake/sleep cycle agreement change habitual consumption beverage food contain caffeine throughout study Body Mass Index ( BMI ) 15 40 kg/m^2 myocardial infarction , congestive heart failure , uncontrolled cardiac arrhythmia within past ≤3 month hospitalization within past ≤4 week major surgical procedure within past ≤4 week participation clinical study involve investigational drug within past ≤4 week current regular use recent ( within past ≤5 year ) past abuse alcohol ( &gt; 14 drinks/week ) illicit drug donation unit blood within past ≤2 week intention donate unit blood study evidence another clinically significant , active pulmonary disorder chronic obstructive pulmonary disease ( COPD ) emergency room treatment asthma within past ≤4 week hospitalization asthma within past ≤8 week respiratory tract infection require antibiotic treatment within past ≤8 week evidence active , clinically significant sinus disease within past ≤1 week history clinically significant psychiatric disorder , stable depression , within past ≤12 week history HIV hypersensitivity intolerance inhaled betaagonists , leukotriene antagonist , leukotriene synthesis inhibitor , ingredient , include lactose galactose clinically unstable disease ophthalmologic , neurological , hepatic , renal , connective tissue , genitourinary , gastrointestinal , cardiovascular hematologic system current cancer history ( within past ≤5 year ) cancer ( except successfully treat basal squamous cell carcinoma skin ) ; cancerfree &gt; 5 year , study participation may allow evidence uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>